Ferozsons Laboratories Delivers Stronger Financial Performance in FY2026
Ferozsons Laboratories Limited recorded a notable improvement in its financial performance during the year ended June 30, 2026, with higher revenue, stronger profitability and improved earnings per share, according to its consolidated financial statements.
The company’s consolidated revenue increased to Rs23.96 billion in FY2026 from Rs18.86 billion in FY2025, representing growth of around 27%. Gross profit also rose substantially to Rs10.70 billion, compared with Rs8.00 billion a year earlier. 283774
Profitability Shows Strong Improvement
Ferozsons Laboratories reported profit after taxation of Rs1.23 billion for FY2026, up from Rs921.71 million in FY2025. This represents an increase of approximately 33%, highlighting a significant improvement in the company’s bottom-line performance.
Profit before income tax increased to Rs2.02 billion, compared with Rs1.53 billion in the previous year. Despite higher administrative and selling and distribution expenses, the company generated stronger profit from operations, which reached approximately Rs2.48 billion, compared with Rs2.13 billion in FY2025. 283774
The improvement also translated into higher earnings for shareholders. Consolidated earnings per share increased to Rs22.51 from Rs17.86, reflecting the stronger profitability recorded during the year.
Comprehensive Income Also Rises
The company’s consolidated total comprehensive income stood at Rs1.29 billion in FY2026, compared with Rs921.71 million in FY2025. Of the FY2026 total, approximately Rs1.04 billion was attributable to the owners of the Group, while Rs255.27 million was attributable to non-controlling interests. 283774
The financial statements also show an additional Rs65.24 million in other comprehensive income, related to the effect of deferred tax on revaluation surplus following a change in the effective tax rate.
Stronger Revenue Base Supports Growth
The increase in revenue was accompanied by a rise in the company’s gross profit, indicating that the stronger top-line performance translated into improved gross earnings. Consolidated cost of sales increased to approximately Rs13.25 billion from Rs10.86 billion, while gross profit expanded by more than Rs2.7 billion year on year. 283774
The company’s standalone results also reflected positive momentum. Ferozsons Laboratories’ standalone revenue increased to Rs15.76 billion from Rs13.86 billion, while standalone profit after taxation rose to Rs650.90 million from Rs528.24 million. Standalone EPS improved to Rs14.97 from Rs12.15. 283774
Cash Flow Position Remains an Important Focus
The consolidated cash-flow statement shows that Ferozsons generated approximately Rs1.49 billion in cash from operations during FY2026. However, after tax and other payments, net cash used in operating activities amounted to approximately Rs428 million. 283774
At the same time, investing activities generated approximately Rs269 million of net cash, compared with net cash used of around Rs1.57 billion in FY2025. The company also recorded significant investment in property, plant and equipment during the year, indicating continued spending on its operational and asset base. 283774
Financial Position
As of June 30, 2026, the consolidated statement showed total equity and liabilities of approximately Rs25.92 billion, compared with Rs24.60 billion a year earlier. Equity attributable to owners of the company stood at approximately Rs13.24 billion, while non-controlling interests amounted to about Rs2.35 billion. 283774
The company’s consolidated long-term secured loans declined to approximately Rs1.09 billion from Rs1.42 billion, although current liabilities remained substantial.
Outlook
Ferozsons Laboratories’ FY2026 results point to a year of solid financial growth, led by a strong increase in revenue and improved profitability. The rise in EPS, together with higher comprehensive income, indicates that the improved performance translated into greater earnings for shareholders.
With consolidated revenue approaching Rs24 billion and profit after tax exceeding Rs1.2 billion, the company enters the new financial year from a stronger earnings position. Continued revenue growth, effective cost management, investment in productive assets and careful management of its financing and cash flows will remain important factors for sustaining this momentum.
Overall, Ferozsons Laboratories’ FY2026 results demonstrate a clear improvement over the previous year, with double-digit growth across key earnings indicators and a stronger contribution from its consolidated operations.
